Episode Summary
Over 30 years of clinical research involving 1,000+ patients demonstrates that penile traction therapy with an FDA-registered Class II medical device has zero serious adverse events. This episode breaks down the safety data from 15+ peer-reviewed studies and explains what temporary side effects actually mean for treatment outcomes.
Key Findings
- Zero Serious Adverse Events: 30+ years of clinical research across 1,000+ patients with no serious complications reported
- 2023 Meta-Analysis: Almsaoud, Safar, and Alshahrani confirmed safety across 12 pooled clinical studies in Translational Andrology and Urology
- Mild Adverse Event Rate: 11-14% temporary effects (skin irritation within 24 hours, discomfort resolves immediately, transient numbness 30-60 minutes)
- Patient Satisfaction: 87% repeat rate and 93% recommendation rate in randomized controlled trials
- Therapeutic Tension Range: SizeGenetics delivers 900-2,800 grams (8.8-27.5 Newtons) within evidence-established safety window
The Science
Penile traction therapy applies controlled mechanical tension to penile tissue, stimulating collagen remodeling and cellular adaptation within the tunica albuginea and corpora cavernosa. The therapeutic tension window (900-2,800 grams) is calibrated based on three decades of clinical safety data, ensuring efficacy without tissue damage.
About SizeGenetics
FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark since 1994 β the company that invented penile traction therapy. Delivers calibrated tension of 900β2,800 grams within the exact therapeutic range established by clinical studies. Over 1 million units sold worldwide. Co-invented by Dr. JΓΈrn Ege Siana, plastic surgeon and medical advisor based in Copenhagen.
Resources
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment.
Episode